Prospects for cervical cancer prevention by human papillomavirus vaccination

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10229-10232

  Schiller, John T ^a,b   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

CANCER MORTALITY; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; LICENCE; PAPILLOMA VIRUS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEX DIFFERENCE; UTERINE CERVIX CANCER; VACCINATION;

CLINICAL TRIALS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 33751260408     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0630     Document Type: Review

References (26)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32:S16-24.
3. Ulmer JB, Liu MA. Ethical issues for vaccines and immunization. Nat Rev Immunol 2002;2:291-6.
4. Freeman H, Wingrove B. Excess cervical cancer mortality: a marker for low access to health care in poor communities. Rockville (MD): National Cancer Institute, Center to Reduce Cancer Health Disparities, NIH Pub. No. 05-5282; 2005.
5. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992;89:12180-4.
6. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol 2003;21:515-46.
7. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
8. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993;262:1448-51.
9. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 1996;7:373-82.
10. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
11. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
12. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intra-epithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
13. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
14. Harper DM, Franco EL, Wheeler C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
15. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
16. Stoler MH. Human papillomavirus biology and cervical neoplasia: implications for diagnostic criteria and testing. Arch Pathol Lab Med 2003;127:935-9.
17. FDA briefing information on HPV vaccine. Vaccines and Related Biological Products Advisory Committee, 2006. Available from: http://www.fda.gov/ohrms/ dockets/ac/06/briefing/2006-4222B3.pdf.
18. Centers for Disease Control and Prevention, National Immunization Program: Advisory Committee on Immunization Practices; 2006 Feb 21-22; Atlanta, Georgia. Available from: http://www.cdc.gov/nip/ACIP/minutes/acip_min_feb_06. doc.
19. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Available from: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.htm.
20. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
21. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
22. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61.
23. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23.
24. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health 2005;37:S17-23.
25. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15.
26. Pastrana DV, Gambhira R, Buck CB, et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005;337:365-72.